Recent News

• 02.20.2026 - Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
• 02.03.2026 - Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026

Recent Filings

• 02.20.2026 - 8-K Current report
• 02.20.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.20.2026 - EX-99.1 EX-99.1
• 02.10.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.09.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.02.2026 - DEFM14A Definitive proxy statement relating to merger or acquisition
• 01.26.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 01.26.2026 - 8-K Current report
• 01.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - PREM14A Preliminary proxy statements relating to merger or acquisition